Cédric Rafat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cédric Rafat has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Alice Doreille
Renal Intensive Care Unit, Department of Nephrology, Hôpital Tenon, Paris, France
6 shared publicationsYosu Luque
Soins Intensifs Néphrologiques et Rein Aigu, Tenon Hospital, AP-HP, Paris, France
5 shared publicationsLaurent Mesnard
Hop Tenon, AP HP, Soins Intens Nephrol & Rein Aigu, Paris, France
4 shared publicationsE. Rondeau
Tenon, AP–HP, Paris, France
3 shared publications- Laurent Mesnard
Soins Intensifs Néphrologiques et Rein Aigu (SINRA), Nephrology Department, Tenon Hospital, Assistance Publique – Hôpitaux de Paris, Paris, France
3 shared publications Marine Dancer
Department de Génétique, Institut Curie, Paris Science et Lettres Université, Paris, France
3 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (2) , 101188
Vancomycin-specific Urinary Immunostaining for Noninvasive Screening of Vancomycin-associated Cast Nephropathy
- 20 November 2025
- Published by Elsevier in Kidney Medicine
- Vol. 8 (2) , 101188
Open AccessVancomycin-specific Urinary Immunostaining for Noninvasive Screening of Vancomycin-associated Cast Nephropathy
- 15 April 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (5) , 1313-1327
Kidney failure care for migrants: a European survey
The management of migrants with kidney failure and no medical insurance raises complex medical, social, financial, and ethical issues. The survey aimed to investigate (i) current practices in managing these patients, and (ii) the perspective of European nephrologists on ethical dilemmas and optimal care. The survey was piloted by the ISN Western Europe Regional Board, with members of the Young Nephrologists' Platform (YNP) of the European Renal Association (ERA), and disseminated to European nephrologists in the ISN and YNP networks. Responses were collected anonymously via SurveyMonkey. A total of 378 responses were collected from 29 European countries. Most (57%) managed fewer than 3 migrant patients with kidney failure per week, while 10% managed more than 11. Most respondents indicated that access to dialysis was unrestricted (59%), although only 25% said migrant patients were systematically eligible for kidney transplantation. Many nephrologists (38%) were unaware of the directives of governmental bodies or hospital protocols regarding migrant patients. The most common obstacles to patient management included language non concordance (64%), uncertainty about the future (56%), and lack of knowledge of medical history (49%). Two-thirds felt managing migrant patients was a moral duty, though 52% reported stress within the clinical caregiving team. Despite strong commitment from European nephrologists, a fragmented legal framework, remaining barriers, and uneven case distribution hinder optimal care for migrant patients with kidney disease.
- 15 April 2025
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 38 (5) , 1313-1327
Kidney failure care for migrants: a European survey
The management of migrants with kidney failure and no medical insurance raises complex medical, social, financial, and ethical issues. The survey aimed to investigate (i) current practices in managing these patients, and (ii) the perspective of European nephrologists on ethical dilemmas and optimal care. The survey was piloted by the ISN Western Europe Regional Board, with members of the Young Nephrologists' Platform (YNP) of the European Renal Association (ERA), and disseminated to European nephrologists in the ISN and YNP networks. Responses were collected anonymously via SurveyMonkey. A total of 378 responses were collected from 29 European countries. Most (57%) managed fewer than 3 migrant patients with kidney failure per week, while 10% managed more than 11. Most respondents indicated that access to dialysis was unrestricted (59%), although only 25% said migrant patients were systematically eligible for kidney transplantation. Many nephrologists (38%) were unaware of the directives of governmental bodies or hospital protocols regarding migrant patients. The most common obstacles to patient management included language non concordance (64%), uncertainty about the future (56%), and lack of knowledge of medical history (49%). Two-thirds felt managing migrant patients was a moral duty, though 52% reported stress within the clinical caregiving team. Despite strong commitment from European nephrologists, a fragmented legal framework, remaining barriers, and uneven case distribution hinder optimal care for migrant patients with kidney disease.
- Open Access
- 24 December 2024
- Published by Elsevier in Kidney Medicine
- Vol. 7 (3) , 100952
Is Amanita phalloides Nephrotoxicity due to Mitochondrial Toxicity?
- 24 December 2024
- Published by Elsevier in Kidney Medicine
- Vol. 7 (3) , 100952
Open AccessIs Amanita phalloides Nephrotoxicity due to Mitochondrial Toxicity?
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2266-2269
Genomic analysis of adult thrombotic microangiopathies in less than 3 days: from rapid to fast genomics to treatment
Using nanopore sequencing, we showed the feasibility and impact of rapid genomic screening for managing thrombotic microangiopathies in 18 prospective cases, achieving diagnoses in <3 days. We compared the results with standard exome sequencing, cost efficiency, and complement blockade initiation.
- 21 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (21) , 2266-2269
Genomic analysis of adult thrombotic microangiopathies in less than 3 days: from rapid to fast genomics to treatment
Using nanopore sequencing, we showed the feasibility and impact of rapid genomic screening for managing thrombotic microangiopathies in 18 prospective cases, achieving diagnoses in <3 days. We compared the results with standard exome sequencing, cost efficiency, and complement blockade initiation.
- Open Access
- 4 May 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (7) , 2306
Response to “Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition”: Still a Long Way to Go
- 4 May 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (7) , 2306
Open AccessResponse to “Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition”: Still a Long Way to Go
- Open Access
- 11 August 2023
- Published by Elsevier in Kidney International Reports
- Vol. 8 (10) , 2136-2140
Role of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry
- 11 August 2023
- Published by Elsevier in Kidney International Reports
- Vol. 8 (10) , 2136-2140
Open AccessRole of the I416L Variant of Complement Factor I in Thrombotic Microangiopathy Among Patients of African Ancestry
- Open Access
- 21 April 2023
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (11) , 2299-2301
Genetic screening in thrombotic microangiopathy: a plea for methylmalonic aciduria with cobalamine C deficiency detection
The recent reviews by Knoers et al. [ 1] highlights the opportunities afforded by massively parallel sequencing (MPS) and lays the groundwork for empowerment of the clinician in his day-to-day exploration of kidney disease.
- 21 April 2023
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 16 (11) , 2299-2301
Open AccessGenetic screening in thrombotic microangiopathy: a plea for methylmalonic aciduria with cobalamine C deficiency detection
The recent reviews by Knoers et al. [ 1] highlights the opportunities afforded by massively parallel sequencing (MPS) and lays the groundwork for empowerment of the clinician in his day-to-day exploration of kidney disease.
- 5 April 2023
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (6) , 1693-1697
Antineoplastic drug-induced immune hemolytic anemia resulting in acute kidney injury: lesson for the clinical nephrologist
- 5 April 2023
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (6) , 1693-1697
Antineoplastic drug-induced immune hemolytic anemia resulting in acute kidney injury: lesson for the clinical nephrologist
- 12 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (2) , 147-155
How I treat thrombotic microangiopathy in the era of rapid genomics
Thrombotic microangiopathy (TMA) encompasses various genetically-driven diseases. The emergence of ultrafast genomic sequencing has recently opened up new avenues of research for genetic investigations in the setting of intensive care units. TMA is likely to be a suitable focus for fast-track genomic sequencing. By establishing an expeditious molecular diagnosis of patients with the complement-dependent hemolytic uremic syndrome, fast-track genomic sequencing allows for the timely implementation or withdrawal of anti-C5 treatment while averting unnecessary, costly, and potentially harmful therapy in patients testing negative for the syndrome. Furthermore, genomics has the potential to reshape the taxonomic classification of TMA owing to comprehensive genomic analysis. The most significant results from such analysis can be categorized as (1) new descriptions of genetic diseases previously not recognized as associated with TMA and (2) an enrichment of the phenotypic spectrum of diseases traditionally related to TMA. The latter draws on the concept of retrophenotyping, wherein genomic investigation precedes full clinical description. By taking precedence over a phenotypic approach, an unbiased genomic-focused analysis maximizes the chances of discovering new descriptions of a given variant. Presented here are 4 cases of TMA which highlight these issues and substantiate the promise of fast-track genomic sequencing.
- 12 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (2) , 147-155
How I treat thrombotic microangiopathy in the era of rapid genomics
Thrombotic microangiopathy (TMA) encompasses various genetically-driven diseases. The emergence of ultrafast genomic sequencing has recently opened up new avenues of research for genetic investigations in the setting of intensive care units. TMA is likely to be a suitable focus for fast-track genomic sequencing. By establishing an expeditious molecular diagnosis of patients with the complement-dependent hemolytic uremic syndrome, fast-track genomic sequencing allows for the timely implementation or withdrawal of anti-C5 treatment while averting unnecessary, costly, and potentially harmful therapy in patients testing negative for the syndrome. Furthermore, genomics has the potential to reshape the taxonomic classification of TMA owing to comprehensive genomic analysis. The most significant results from such analysis can be categorized as (1) new descriptions of genetic diseases previously not recognized as associated with TMA and (2) an enrichment of the phenotypic spectrum of diseases traditionally related to TMA. The latter draws on the concept of retrophenotyping, wherein genomic investigation precedes full clinical description. By taking precedence over a phenotypic approach, an unbiased genomic-focused analysis maximizes the chances of discovering new descriptions of a given variant. Presented here are 4 cases of TMA which highlight these issues and substantiate the promise of fast-track genomic sequencing.
- 18 August 2022
- Published by Elsevier in Kidney International
- Vol. 102 (3) , 669-670
Could Plasmodium falciparum–related kidney disease stand as another example of interferonopathy?
- 18 August 2022
- Published by Elsevier in Kidney International
- Vol. 102 (3) , 669-670
Could Plasmodium falciparum–related kidney disease stand as another example of interferonopathy?